About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, March 19th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

Champion Industries, Inc. (CHMP)

WePickPennyStocks, Super Nova Stock Picks, Super Hot Penny Stocks, Winning Penny Stock Picks, PennyStockPickReport, PennyStockPickAlert, PennyStockMoneyTrain, and Liquid Tycoon reported recently on Champion Industries, Inc. (CHMP), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Champion Industries, Inc. is a commercial printer, business forms manufacturer, and office products and office furniture supplier in regional markets east of the Mississippi. The Company also publishes The Herald-Dispatch daily newspaper in Huntington, West Virginia. Champion Industries is based in Huntington. The Company and their predecessors have been headquartered in Huntington, West Virginia since 1922. The Company offers their products through a sales force, wholesalers' national catalogs, and the Internet. They offer these products to manufacturers, institutions, financial services companies, and professional firms.

Champion Industries has several companies/divisions. These include Chapman Printing (West Virginia and Kentucky); Stationers, Champion Clarksburg, Capitol Business Interiors, Garrison Brewer, Carolina Cut Sheets, U.S. Tag and Champion Morgantown (West Virginia); Champion Output Solutions (West Virginia), and Chapman-Merten Co.(Kentucky and Ohio). These also include Smith & Butterfield (Indiana and Kentucky); Champion Graphic Communications (Louisiana); Donihe Graphics (Tennessee); Blue Ridge Printing (North Carolina) and Champion Publishing (West Virginia, Kentucky and Ohio).

Champion involves in printing business cards, letterheads, and envelopes, and one, two, or three-color brochures. They also print process color manufacturing brochures, posters, advertising sheets, and catalogues; die cutting and foil stamping; forms printing of roll-to-roll computer forms, checks, invoices, and purchase orders, and forms in single-part, multi-part, continuous, and snap-out formats. They also involve in tag and label manufacturing and Web printing of brochures and catalogs.

The Company also provides bindery services, including trimming, collating, folding, and stitching of the final product; and output solutions, including print on demand, inserting, and mailing services. Additionally, they offer supplies, including file folders, paper products, pens and pencils, computer paper and laser cartridges; furniture, including budget and middle price range desks, chairs, file cabinets, and computer furniture; and design services, such as space planning, purchasing and installation of office furniture, and management of design projects.

Last week, Champion Industries announced a net loss from continuing operations of $(3.3) million or $(0.29) per share on a basic and diluted basis for the quarter ended January 31, 2013. This is compared to a net loss from continuing operations of $(83,000) or $(0.01) per share on a basic and diluted basis for the quarter ended January 31, 2012. They reported a net loss from discontinued operations for the quarter ended January 31, 2013 of $(291,000) compared to a net loss from discontinued operations for the quarter ended January 31, 2012 of $(3,000) or $(0.02) and $(0.00) on a basic and diluted per share basis.

The results reflected a substantial decrease in earnings mainly due to pre-tax non-cash impairment charges associated with goodwill of $(2.2) million associated with the printing segment and higher interest costs primarily associated with the amortization of debt discount associated with warrants issued to the Company's secured lenders.

Champion Industries, Inc. (CHMP), closed Tuesday's trading session at $0.14, up 16.67%, on 8,500 volume with 4 trades. The average volume for the last 60 days is 29,709 and the stock's 52-week low/high is $0.05/$0.65.

Bering Exploration, Inc. (BERX)

Money Morning and SmallCapVoice reported earlier on Bering Exploration, Inc. (BERX), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Bering Exploration, Inc. engages in the exploration, acquisition, development, and production of natural gas and crude oil. The Company's initial concentration is on drilling prospects along the Texas and Louisiana Gulf Coast. Bering Exploration's strategy includes acquiring onshore domestic production and drilling opportunities. The Company has their headquarters in Houston, Texas. Bering Exploration lists on the OTC Markets' OTCQB.

The Company has leased the mineral rights on approximately 1,200 gross acres targeting the Eagle Ford shale play in Central Texas with potential gross reserves of 3,000,000 barrels of oil and 120 well locations. Prospects for the Company include the Singer Project
Beauregard Parish, Louisiana (320 Acres); the Ashland Project,
Concordia Parish, Louisiana (1,200 acres); the Gohlke NE Project,
Dewitt County, Texas (272 acres); the Luling Project, Caldwell County, Texas (1284 acres), and the Chicas Locos Project, Victoria County, Texas (640 acres).

In February 2013, Bering Exploration announced that they completed an additional production test conducted at the conclusion of the re-completion performed on one of the Company's wells on their North Edna prospect. Bering received additional well test results that showed shut in pressure of 2,994 psi; the well flowed at 654 MCF per day on a #7 choke at 2914 tubing pressure. It had a recovery rate of 4.33 barrels per day of condensate, 600 gallons per day recovered natural gas liquids (NGL), and no water from a virgin zone in this formation. 

Earlier this month, Bering Exploration announced that they entered into a right of way agreement with the landowner of their North Edna prospect. The right of way is required for the construction of Bering's proposed pipeline to tie in with a first purchaser for the sale of the natural gas from the recently completed well in the Company's North Edna prospect.

The 384-acre prospect is in Jefferson Parish, Louisiana. It has potential gross reserves of the equivalent of 1 million barrels. Based upon today's prices, this equates to a gross value of more than $90 million dollars.

Bering Exploration, Inc. (BERX), closed Tuesday's trading session at $0.19, up 9.83%, on 48,180 volume with 10 trades. The average volume for the last 60 days is 220,169 and the stock's 52-week low/high is $0.10/$0.95.

Oryon Technologies, Inc. (ORYN)

DrStockPick, PennyOmega, PennyToBuck, StockHotTips, BestOtc, and Penny Stocks Profile reported this week on Oryon Technologies, Inc. (ORYN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Oryon Technologies, Inc. is developing and commercializing a three-dimensional, elastomeric, electroluminescent (EL) technology, patented and trademarked under the name ELastoLite®. The creation of ELastoLite® was to replace conventional EL with a highly malleable, flexible and economical elastomeric EL lamp, which is ultra-thin, elastic, washable, and heat-resistant so that it could be applied directly to fabrics. ELastoLite® enables thin, flexible, crushable, water-resistant lighting systems to undergo incorporation into multiple applications. This includes safety apparel, sporting goods, consumer goods and membrane switches, and others.

Founded in 1997, Oryon Technologies' shares trade on the OTC Markets' OTCQB. The Company has their corporate headquarters in Addison, Texas. In 2002, Oryon acquired the initial elastomeric electroluminescent lighting technology patents and intellectual property. The Company incorporated (Nevada) on May 16, 2008. Their technologies are protected by more than 55 patents issued or pending globally. Oryon is a Research and Development (R&D) company as well as a sales and marketing company.

Essentially, ELastoLite® is an innovative next generation electroluminescent (EL) lamp. It is three-dimensional, elastomeric, membranous Polymer Thick Film (PTF). It is printed directly on almost any surface and is a polyurethane ink structure. Oryon Technologies is initially focusing on developing solutions for the textile, apparel (sports and safety), and membrane switches industries. The Company is also looking to expand into molded specialty products. This includes applications for the defense, automotive and point-of-sale (POS) sectors.  Oryon's ELastoLite® has been featured in apparel products sold by Nike, Lands' End and Marmot Mountain Ltd.

Oryon Technologies will look for industry partners to either co-develop or license ELastoLite® technology in promising new high technology fields that require extended developmental periods. These specific fields include biometric fingerprint sensors in which Oryon holds two promising patents, high-speed roll-to-roll printing that will allow the Company to offer cost effective solutions for floor lighting, greeting cards, printed flexible batteries and solar cells. The Company has a new digital printing process. They now print custom digital quality images with lower minimums, higher resolution and shorter lead times.

Oryon Technologies has entered into an agreement with Rebel Athletic, an industry-leading manufacturer of custom and couture cheerleading uniforms and apparel, for exclusive representation to the cheerleading and dance industries in the U.S., Japan and Australia. ELastoLite® will be featured on the uniforms of two Rebel Athletic-sponsored teams at the upcoming World Cheerleading Competition to be held April 25-26, 2013 in Orlando, Florida.

Oryon Technologies, Inc. (ORYN), closed Tuesday's trading session at $0.36, up 2.86%, on 507,269 volume with 160 trades. The stock's 52-week low/high is $0.13/$1.33.

Southern Products, Inc. (SNPD)

PennyStockClub, The Stock Scout, Penny Stock Pros, PennyStocks24, Penny Stock VIP, Preferred Penny Stocks, Wallstreetbuzz, Orbit Stocks, Otcstockexchange, Whisper from Wall Street, and Center Stage Stocks reported recently on Southern Products, Inc. (SNPD), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2010, Southern Products, Inc. is a consumer electronics company headquartered in City of Industry, California. They engage in the design, assembly, import, marketing, and sale of flat panel televisions under the Sigmac brand name. Southern Products distributes flat-panel televisions and peripherals through big-box retailers in the U.S. The Company has a product line of more than 20 flat-panel models in production.

Southern Products' mission is to establish a globally recognized line of consumer electronic products. The Company has entered into large-scale distribution agreements with Target, K-Mart, Costco.com, Tiger Direct, Newegg and Walmart.com for the sale of Sigmac-branded flat-panel televisions, Tablets, Picture Frames and accessories in North America.

Pertaining to Liquid Crystal Display (LCD) products, they offer the NE42AB model for watching movies and TV shows in HD quality with 1080p and 3 HDMI inputs. This product mounts on a stand or on a wall. The screen size of the NE42AB product is 42.00 inches. Their NE32AB1 TV produces a native 1080p HD resolution displaying clear crisp HD images with multiple video inputs, including 3 HDMI connections.

Their SC39AB product offers high-level video and audio entertainment. The screen size of this particular product is 38.50 inches. Furthermore, their SC32AB LCD HDTV has multiple video inputs, including 3 HDMI connections. A user can be flexible in connecting their existing multimedia components.

Pertaining to Light-Emitting Diode (LED) products, the Company offers their LE55ABD1, LE55ABD, LE42AB1, and SE42AB products. The LE55ABD1 product offers a 3D entertainment experience. It has a screen size of 54.65 inches. The LE55ABD product enables users to enjoy movies, video games and more in 3D. The LE42AB1 offering is an LED TV suited to fit into one's office or dorm room, as is the SE42AB product. The Company also has additional product offerings in the LED category.

Today, Southern Products announced a new agreement with Kontech, LLC. This agreement is for the design and production of a Sigmac line of commercial televisions and displays. One of Kontech's distinctive manufacturing abilities is the production of enhanced brightness for indoor and outdoor televisions, up to 10 times the standard.

Southern Products, Inc. (SNPD), closed Tuesday's trading session at $0.205, up 10.81%, on 1,324,061 volume with 216 trades. The average volume for the last 60 days is 95,022 and the stock's 52-week low/high is $0.18/$1.00.

Azia Corp. [Axxess Unlimited, LLC] (AXXU)

FeedBlitz, USA Market News, Top Gun, The Stock Psycho, AimHighProfits, PennyStockShark, StockProfessors, and PennyStockRewards.com reported earlier on Azia Corp. [Axxess Unlimited, LLC] (AXXU), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Azia Corp. (Axxess Unlimited, LLC) provides actionable, next-generation business intelligence for a broad spectrum of businesses and organizations. Last week, Azia announced that they signed a Definitive Agreement to acquire Axxess Unlimited, LLC. Axxess Unlimited is a next generation business intelligence company. Shareholders approved the transaction. The final step, independent of the close of the transaction, will be to change the corporate name to Axxess Unlimited. Azia (Axxess Unlimited) lists on the OTC Pink Current Information. The Company has their headquarters in Scottsdale, Arizona, and they have an office in Los Angeles, California.

The Company is a provider of information-driven business solutions via interactive marketing, interactive technologies, application and product development, customer relationship management (CRM), business intelligence, portals and collaboration, as well as infrastructure solutions.

The Axxess Ad Tracker, launched in May of 2012, leads their digital marketing platform. Ad Tracker is the first acquisition-focused ad tracking technology that allows companies to track responses across multiple advertising mediums. The Company's tightly integrated proprietary technology platform enables companies to manage all of their digital marketing efforts easily while reaching, engaging and gaining knowledge about their customers.

Yesterday, Axxess Unlimited announced that they signed a Letter Of Intent (LOI) to acquire TDG, Inc. and TDG Brands, Inc. TDG creates brand-led growth and productivity solutions for their clients at key points along the business value chain. TDG assists brand leaders in fully realizing and successfully implementing team, department or company-wide sales and branding objectives.

Today, Axxess Unlimited announced that they signed a contract with Michelle Cosmetics, LLC to launch a new retail line of premium skincare products called "MCMichelle." Michelle selected Axxess as the partner to launch their total retail line, using Axxess' suite of digital marketing tools. This includes the Company's patent-pending SEO technology, viral social media campaigns, and strategic partnerships. 

Michelle Cosmetics formulates and manufactures an assortment of department-store quality moisturizers, anti-cellulite, anti-aging, hair removers and skin soothing products. Axxess will receive a percentage of all gross revenues generated on www.MCMichelle.com.

Azia Corp. [Axxess Unlimited, LLC] (AXXU), closed Tuesday's trading session at $0.625, up 9.65%, on 14,568 volume with 14 trades. The average volume for the last 60 days is 9,113 and the stock's 52-week low/high is $0.40/$1.75.

Los Andes Copper Ltd. (LA.V)

Today we are reporting on Los Andes Copper Ltd. (LA.V), here at the QualityStocks Daily Newsletter.

Los Andes Copper Ltd. is an exploration and development company whose shares trade on the TSX Venture Exchange. The Company is focusing on the acquisition, exploration and development of advanced stage copper deposits in Latin America. Los Andes is concentrating on the Vizcachitas porphyry copper-molybdenum project located 120 kilometers north of Santiago, Region V, Chile. Los Andes Copper is based in Vancouver, British Columbia.

The Company's Vizcachitas porphyry copper-molybdenum project is in an area of good infrastructure. This infrastructure includes available water, road access to the site, power approximately 40 kilometers away, as well as ports and smelters within 200 kilometers. The Vizcachitas project consists of three exploration concessions and 33 exploitation concessions. They cover an area of approximately 59 square kilometers. During 2010, Los Andes Copper fulfilled the requirements of the option agreement and consolidated the property ownership. Therefore, they now own 100 percent of all 36 concessions.

The Vizcachitas property contains an NI 43-101 compliant indicated resource of 515M tonnes grading 0.39 percent Cu (4.4 billion pounds) and 0.011 percent Mo (125 million pounds). It contains an inferred sulphide resource of 572M tonnes grading 0.34 percent Cu (4.3 billion pounds) and 0.012 percent Mo (151 million pounds) at a 0.3 percent copper equivalent cut-off.  

The Vizcachitas deposit is in the prolific central Chile Late Miocene-Pliocene metallogenic belt. This belt also includes the world class El Teniente (78.64Mt Cu), Los Pelambres/El Pachon (26.42Mt Cu) and Rio Blanco/Los Bronces (52.43Mt Cu) deposits. The Vizcachitas deposit has the potential for a low strip open pit operation.  

In August of 2012, Los Andes Copper announced that they received $1,950,000 upon the exercise of 13,000,000 stock purchase warrants of the Company.  Turnbrook Corp. exercised the Warrants at a price of $0.15 each. These were exercisable on or before December 21, 2013. 

Los Andes is using the proceeds received to fund exploration and development work on their Vizcachitas project, and for general working capital purposes. 

Los Andes Copper Ltd. (LA.V), closed Tuesday's trading session at $0.26, down 10.34%, on 2,000 volume. The stock's 52-week low/high is $0.19/$0.38.

Cavitation Technologies, Inc. (CVAT)

UndiscoveredEquities reported earlier on Cavitation Technologies, Inc. (CVAT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTC Markets' OTCQB, Cavitation Technologies, Inc. (CTi) designs and manufactures state-of-the-art, flow-through, robust devices and systems. The Company (a "GreenTech" development stage entity) also develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algal oil extraction, alcoholic beverage enhancement, as well as water treatment. Hydrodynamic Technology, Inc. is a wholly owned subsidiary of the Company. Founded in 2007, Cavitation Technologies has their corporate headquarters in Chatsworth, California.  

The Company's patented Nano Reactor®, as an add-on to existing neutralization systems, allows refiners to reduce significantly processing costs and the environmental impact, while also increasing the yield. Cavitation Technologies has commercialized their patent-pending CTi Nano Neutralization® process. The Nano Reactor® is the critical component of the Nano Neutralization System - a vegetable oil refining system designed to reduce operating costs and increase yields.

CTi engages in merchandising their NANO Neutralization System designed to help refine vegetable oils such as soybean, canola, and rapeseed. The Desmet Ballestra Group has partnered with CTi to market this innovative technology globally to large-scale facilities. Management's plan is to generate income from operations by licensing their technology around the world through the Desmet Ballestra Group.

Last month, Cavitation Technologies announced that the Desmet Ballestra Group entered into a sales agreement with an edible oil refinery in Argentina that produces vegetable oil. The purchased system, capable of processing 300 tons of oil daily, will undergo installation in the third fiscal quarter of 2013.

CTi received the initial down payment in the second quarter of the current fiscal year. They expect to receive additional revenue from the sales agreement in the third and fourth quarters of the current fiscal year. The Desmet Ballestra Group has been CTi's strategic partner since 2010. They are the licensee of CTi's vegetable oil refining technology.

Cavitation Technologies, Inc. (CVAT), closed Tuesday's trading session at $0.038, even for the day, on 240,700 volume with 29 trades. The average volume for the last 60 days is 209,915 and the stock's 52-week low/high is $0.0098/$0.099.

Casablanca Mining Ltd. (CUAU)

BUYINS.NET reported last week on Casablanca Mining Ltd. (CUAU), Penny Stocks VIP, SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, CRWEWallStreet, CRWEFinance, StockHotTips, CRWEPicks, PennyToBuck, DrStockPick, PennyOmega did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQX U.S., Casablanca Mining Ltd. engages in the acquisition, exploration, development, and operation of precious metal properties in South America. They accomplish this through their wholly owned subsidiary Santa Teresa Minerals, S.A. Their gold and copper mining operations are based near Santiago, Chile. Casablanca Mining has their corporate headquarters in Santee, California. In addition, they have an office in Santiago, Chile.

Casablanca Mining's Santa Teresa Minerals has, directly and indirectly through different equity interests, mining rights in 80 different mining and mineral exploration properties. These include gold, copper and copper sulfate. Santa Teresa Minerals has mining rights in exploration projects, "Free Gold", the "Casuto Project," consisting of Los Azules 1-3, Tauro 1-6, Los Chipi 1-22, and the "New Gold Project," consisting of Los Pinos 1-30 and Teresita 1-20. The Company also has a 50/50 revenue-share at the now operational "San Jose Las Dichas" alluvial gold mine.
 
Santa Teresa Minerals has acquired the option to purchase 80 percent of the Las Palmas gold mine (consisting of Keyla Uno 1-20 and Keyla Dos 1-34) in Chile. The Company has the right to begin immediately mining the Property during a one-year option period. They may continue to make purchase payments over a period of 30 months to acquire Las Palmas or decline to purchase the property. The Property is in IV Region Coquimbo, Choapa Province, Chile. It consists of 2 non-contiguous surveyed blocks totaling 158 hectares.

Last month, Casablanca Mining announced that their wholly owned subsidiary, Santa Teresa Minerals, completed a detailed review of the mineral exploration and development potential of their Las Palmas Gold Property. Gran Pacific Minerals commissioned the 43-101 report; it is detailed in a National Instrument 43-101 - Standards of Disclosure for Mineral Projects - entitled "NI 43-101 Technical Report on the Las Palmas Property, Coquimbo, Choapa Province, Chile".

Casablanca Mining Ltd. (CUAU), closed Tuesday's trading session at $0.68, up 13.33%, on 447,273 volume with 197 trades. The average volume for the last 60 days is 121,822 and the stock's 52-week low/high is $0.051/$2.40.

graphic

The QualityStocks
Company Corner

graphic
graphic

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.31, up 6.90%, on 300,681 volume with 95 trades. The stock’s average daily volume over the past 60 days is 194,982, and its 52-week low/high is $0.161/$0.65.

International Stem Cell Corp. was happy to deliver some encouraging efficacy and safety data out of their recent pilot study of in rodent and non-human primate models of Parkinson's disease, which utilized the company's human parthenogenetic stem cell therapy technology. This study is a first, key step toward a cell-based Parkinson's therapy and represents the foundational work necessary to embark upon even more rigorous clinical trials. Subsequent to implantation of the neuronal cells in both animal models in this study, subjects in the test group managed to produce solid safety and efficacy results, roundly confirming ISCO's hypothesis.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Announces Positive Results of Primate Parkinson's Study

International Stem Cell Corporation Technology for Deriving Neuronal Cell Published by Nature Publishing Group

International Stem Cell Corporation Raises Additional Capital

Soul and Vibe Interactive, Inc. (SOUL)

The QualityStocks Daily Newsletter would like to spotlight Soul and Vibe Interactive, Inc. (SOUL). Today, Soul and Vibe Interactive, Inc. closed trading at $0.32, up 5.96%, on 36,262 volume with 15 trades. The stock’s average daily volume over the past 60 days is 207,474, and its 52-week low/high is $0.26/$1.45.

Soul and Vibe Interactive Inc. reported on a key aspect of their business model today as sales of monetized game-related content were highlighted. In-game virtual apparel, costumes, and props for avatars will generate additional income streams, playing off the inherent drive for customization and uniqueness among players with an Avatar Marketplace, similar to the implementation Microsoft used for Xbox Live. The idea is to roll out Avatar item collections in concert with game titles, adding to the richness of content developed around the IPs of the SOUL's licensed-brand partners, like General Mills.

Soul and Vibe Interactive, Inc. (SOUL) is a publisher of games and game-related content for consoles, mobile devices, and personal computers. The company specializes in creating original intellectual properties and has extensive experience licensing world-renowned brands from influential companies. Notably, Soul and Vibe is the only company with the right to license General Mills brands for video game applications. 

Leveraging partnerships with software developers around the world, Soul and Vibe transforms unique concepts into engaging and affordable entertainment experiences. The game publisher has established game development and publishing agreements for the Xbox 360® video game and entertainment system, Windows 8, Windows Live, and Windows Phone from Microsoft, and the PlayStation® 3 computer entertainment system and PlayStation® Vita (PS Vita) from Sony.

Soul and Vibe stands out from the crowd by breaking through marketplace clutter and noise via direct-to-consumer tactics that reverberate from the core player to the mainstream gaming audience. Making games as fun to talk about as they are to play is a key focus of the company. The more personable and memorable the play experience, the more likely consumers and press will talk about the game and its publisher.

The burgeoning game industry spans across diverse demographics and offers wide-ranging opportunities for profit and growth. Consumer spending on console, mobile, and personal computer game software exceeded $56 billion in 2010 and is projected to reach $82 billion by 2015. This revenue represents more than 2x the size of the music industry and nearly 3/5th the size of the entire film industry. Disclaimer

Soul and Vibe Interactive, Inc. Company Blog

Soul and Vibe Interactive, Inc. News:

Soul and Vibe to Monetize Avatars to Create Marketing Impressions and Additional Revenues

Soul and Vibe's Mobile Games to Serve as Revenue-Generating Marketing Vehicles for Its High-Value Console and PC Games

Soul and Vibe Selected to Publish Games on Xbox 360 and PlayStation 3

The Guitammer Company Inc. (GTMM)

The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.19, up 11.76%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 17,071, and its 52-week low/high is $0.082/$0.35.

The Guitammer Company Inc. announced securing yet another theatre installation with Sichuan Lumičre Cinema Co. Ltd. (Lumičre Pavilions) of Beijing, China, making it the eighth such installation for the company. This new installation will be a retro-fit upgrade as the ButtKicker®-brand "4D" system is fitted to all 330 seats in one auditorium in Hangzhou bringing total market penetration to some 1,380 seats in eight different locations.

The Guitammer Company Inc. (GTMM) is a leader in low frequency sound products and technology. Its innovative and award winning line of patented ButtKicker-brand low frequency audio transducers let users feel low-frequency sound (bass). ButtKicker brand products are used around the world by leading entertainment and theater companies such as AMC, IMAX and Disney in movie theaters and attractions; by world-famous musicians; in home theaters, simulators and for car audio.

ButtKicker brand products are distributed by Pearl Drums for musicians under the trade name, "Pearl's Throne Thumper by ButtKicker", and factory installed in home theater seating by Palliser Furniture. ButtKicker brand products' patented design makes them musically accurate, powerful and virtually indestructible. The Company is headquartered in Westerville, OH.

The Guitammer Company's newly patented broadcast technology, ButtKicker LIVE! enables the excitement, impact and feeling of sporting events to be broadcast along with the sound and video. ButtKicker LIVE! puts you into the action, whether you're at home or at the event.

ButtKicker Live! technology is available for cable, satellite, fiber optic, IPTV and over-the-air broadcast and has been successfully tested with several major content (sports) providers. ButtKicker(r) and ButtKicker Live!(r) are registered trademarks of The Guitammer Company. Disclaimer

The Guitammer Company Inc. Company Blog

The Guitammer Company Inc. News:

Lumiere Pavilions Jump Starts Chinese New Year With Eighth Theater Installation of Guitammer's Patented "4D" Technology

The Guitammer Company Announces Strong 2012 Financial Results

Guitammer and State of Ohio Modify Terms of "Innovation Loan"

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.80, up 6.67%, on 5,200 volume with 2 trades. The stock’s average daily volume over the past 60 days is 3,291, and its 52-week low/high is $0.06/$2.80.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D™ at Society of Toxicology's 52nd Annual Meeting

VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting

VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D™

International Stem Cell Corp. (ISCO) Reports Positive Results of Primate Parkinson’s Study

International Stem Cell Corp., a biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSC), this morning announced the safety and encouraging efficacy of its stem cell therapy in rodent and non-human primate models of Parkinson’s disease.

“This pilot study represents a first essential step in bringing cell-based therapies for Parkinson’s disease to clinical trials,” stated co-author of the study Evan Y. Snyder, MD, PhD, Director of Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute.

Designed to demonstrate the viability, fate, and functional efficacy of the stem cell derived neural cells after implantation to the brain, these placebo-controlled studies involved highly pure populations of neuronal cells that were differentiated from hpSCs according to the protocol developed by ISCO and recently published in the Nature Publishing Group’s Scientific Reports.

The studies employ MPTP-lesioned African Green monkeys and 6-OHDA-lesioned rats, the principle models used to study Parkinson’s disease. The duration of the primate study was four months and the rodent study six months. In the non-human primate model, behavioral endpoints were assessed with parkinsonian scores. These scores, based on a standardized rating scale, were recorded by observers blinded to whether the primates were in the treatment or control group. Observations were done twice per day, five days per week. In the rodent model, behavioral improvement was assessed using the cylinder test, amphetamine, and apomorphine induced rotation tests. Cell engraftment, viability, and phenotype of the implanted cells were determined histologically at the end of the studies. Tumorigenicity and safety of the therapy was assessed at the end of both the rodent and primate studies by gross necropsy and brain histology.

Following the implantation of the neuronal cells, all monkeys in the treatment group had higher levels of dopamine in the brain compared with the control group. Additionally, the rats in the treatment group showed gradual improvements in motor symptoms consistent with cells survival, engraftment, and dopamine release. No adverse events, including dyskinesia, deformations, tumors, or overgrowth, were observed in the rat or monkey treatment groups. These exciting results provide solid evidence that hpSC-derived neuronal cells can be safe and have a disease modifying effect. Although preliminary, these results further support the belief that ISCO’s approach to Parkinson’s disease treatment is highly promising.

“These results are pivotal for our pre-clinical Parkinson’s program showing, as they do, that the hpSC-derived neuronal cells can potentially ameliorate the behavioral symptoms without triggering dyskinesias. This data forms the foundation of our discussions with the FDA as we move towards our IND in 2013,” said Dr. Ruslan Semechkin, Principal Investigator of this study, head of R&D for International Stem Cell Corporation and Member of the American Academy of Neurology.

According to today’s press release, these results will be presented and discussed at the 65th American Academy of Neurology Annual Meeting, one of the world’s most important annual events for neurologists and neuroscience professionals and the largest such international meeting of its kind with more than 12,000 attendees at last year’s meeting.

Location: San Diego Convention Center, 111 W Harbor Dr., San Diego, CA 92101
Session: Movement Disorders; Parkinson’s Disease Therapeutics
Date and time: March 20th, 2012 at 3:30 PM PDT

For more information on ISCO’s hpSC technology and the Parkinson’s disease study, visit www.internationalstemcell.com

Soul and Vibe Interactive, Inc. (SOUL) Reports Plan to Monetize Avatars for Marketing Impressions and Additional Revenues

Soul and Vibe Interactive, a publisher of games for consoles, mobile devices, and personal computers, today told investors that its business model includes selling monetized games-related content, including virtual apparel, costume, and prop collections for Avatars. In addition to generating an additional stream of revenue, Avatar items can promote brand awareness for Soul and Vibe’s games and intellectual properties.

Avatars, the digital representation of gamers, have grown in popularity across many computer and console platforms. Microsoft, for example, launched its Avatar Marketplace on Xbox Live in 2009. Through this online marketplace, users buy virtual apparel including t-shirts, shoes, accessories, and costumes. They can also purchase props such as pets, hand-held toys, and miniaturized ride-on vehicles based on gaming intellectual properties, pop-culture, and licensed-brands. Each Avatar item sold is a marketing impression for the game and IP with which it is associated for the 55+ million Xbox Live subscribers online.

“Soul and Vibe intends to sell Avatar item collections in conjunction with each game we release. Avatar items based on the IPs of our licensed-brand partners, like General Mills, and our own proprietary IPs, is an ideal way for us to expand awareness for each of our games,” stated Soul and Vibe’s CEO and President, Peter Anthony Chiodo (“Tony”).

“As a form of monetized games-related content, Avatar items are one form of revenue generating marketing vehicle that can provide an additional revenue stream for the Company. We also intend to develop and monetize in-game consumables and downloadable content that enhances and expands the experience for gamers,” Chiodo added.

For more information, visit www.soulandvibe.com

Leading Chinese Luxury Cinema Operator to Upgrade 330 Additional Seats with The Guitammer Company, Inc. (GTMM) Experience

The Guitammer Company, a leader in low frequency sound products and technology, today reported that it has secured its eighth theater installation with Sichuan Lumière Cinema Co. Ltd. (Lumière Pavilions) of Beijing, China.

A retro-fit upgrade, this installation will add the ButtKicker “4D” system to all 330 seats in one auditorium of Lumière’s existing eleven auditorium theater complex in Hangzhou City, Zhejiang Province. Once the installation is completed, the total number of Lumière Pavilions seats that feature Guitammer’s ButtKicker immersive technology will increase to nearly 1,400 seats in eight different locations. Today’s press release hinted that additional installations are expected.

Unlike other offerings that require the costly installation of new seats, Guitammer’s solution can be added to almost any existing theater seating. Combined with the tremendous results achieved after previous installations, this “retro-fit” differentiator was one of the key reasons Lumière decided to upgrade this existing auditorium.

“After hearing of the many positive responses Lumière received from its patrons who experienced our ButtKicker ’4D’ theater, it is no surprise that the imprint of our exciting technology continues to grow in China,” Mark Luden, President of Guitammer, stated. “I expect our international footprint will continue to expand as cinemas around the globe seek out and invest in new technologies that provide a differentiated and enhanced user experience.”

To watch and listen to Guitammer’s interview with the general manager of Nanjing Cinema, Lumière Pavilions, visit http://www.guitammer.com/michellezhou.html.

Guitammer’s “4D” technology enables audiences to experience first-hand the excitement, impacts, and special effects for an immersive entertainment experience. More than 10,000 seats at over 86 different entertainment locations in 11 countries are now ButtKicker-enabled, including movie theaters in the U.S., Russia, South Korea, and China.

For more information, visit www.guitammer.com

Advaxis, Inc. (ADXS) Leverages the Immune System

The human body’s primary defense against diseased cells is a strong immune system, a complex system of cellular level processes that has evolved to both identify and take action against foreign or diseased cells, including cells developing into cancer cells. It is believed that the human body is constantly generating at least some cancer cells, but that the body’s immune system is generally able to handle them. However, a defective immune system, a system compromised by a genetic problem, or environmental factors, or weakened by changes related to the aging process, leaves the body vulnerable to internal or external attack.

For example, it appears that an aging immune system is simply less effective in dealing with cancer cells, although the reasons for this are still not fully understood. As a result, cancer is much more common in people over 60. The immune system must have the ability to both identify and destroy problem cells, and if either of these roles is compromised, the result can be full blown disease.

But science is now learning how to leverage the many remarkable abilities of the human immune system, tweaking it in such a way as to help it identify and then take successful action against cancerous and other corrupted cells. Immunotherapy is just now beginning to appear on the public stage with treatments that partner with the body instead of fighting it.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology involving the use of live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) that redirect the powerful immune response all human beings have to the bacterium to the cancer itself. In effect, the approach puts cancer in the line of fire.

ADXS-HPV, the company’s main anti-cancer drug, is currently being evaluated in 5 clinical trials for HPV-associated diseases, including cervical cancer, head and neck cancer, and anal cancer, and the company has over 15 distinct constructs in various stages of development.

For additional information, visit www.Advaxis.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Xtremepicks
(CPLY)

2.

Real Pennies
(VYEY)

3.

OtcWizard
(CAON)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251